Danaher Corporation $DHR Stock: Sterling Capital Management LLC Lowers Position

Sterling Capital Management LLC lessened its stake in Danaher Corporation (NYSE:DHR) by 20.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 52,581 shares of the conglomerate’s stock after selling 13,739 shares during the quarter. Sterling Capital Management LLC’s holdings in Danaher were worth $11,649,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in Danaher in the 2nd quarter valued at $10,492,520,000. Jupiter Topco LLC purchased a new stake in shares of Danaher during the 2nd quarter valued at approximately $1,456,317,000. Generation Investment Management LLP acquired a new position in shares of Danaher in the 2nd quarter valued at $1,287,949,000. Bank of America Corp DE purchased a new position in Danaher during the second quarter worth about $993,846,000. Finally, Legal & General Group Plc acquired a new stake in Danaher in the 2nd quarter valued at approximately $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

Danaher Stock Performance

Danaher stock traded up $0.61 during trading hours on Friday, reaching $230.36. 3,935,897 shares of the stock were exchanged, compared to its average volume of 4,912,513. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm’s 50 day moving average is $216.32 and its 200 day moving average is $197.35. The stock has a market cap of $161.94 billion, a P/E ratio of 37.70, a P/E/G ratio of 2.87 and a beta of 0.76. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.25 and a current ratio of 1.63.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.89 EPS. Analysts predict that Danaher Corporation will post 8.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 26.19%.

Analyst Ratings Changes

DHR has been the topic of several analyst reports. Morgan Stanley increased their price objective on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Guggenheim boosted their target price on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Wells Fargo & Company reduced their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Finally, Citigroup increased their target price on shares of Danaher from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $242.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.